Literature DB >> 10805970

Aminopeptidase N/CD13 is directly linked to signal transduction pathways in monocytes.

A N Santos1, J Langner, M Herrmann, D Riemann.   

Abstract

In the present study, we characterized in monocytes the rise in [Ca(2+)](i) evoked by monoclonal antibodies (mAbs) to aminopeptidase N (APN)/CD13, showing a two-phase calcium increase with a small-belled [Ca(2+)](i) rise due to the release of calcium from intracellular stores and a more sustained plateau due to the influx of calcium from the extracellular environment. Tyrosine kinase inhibitors were able to inhibit the rise in [Ca(2+)](i) induced by ligation APN/CD13, as were inhibitors of the phosphatidylinositol 3-kinase. For the first time we can show that mAbs to APN/CD13 provoke phosphorylation of the mitogen-activated protein kinases ERK1/2, JNK, and p38. Furthermore, we show that mRNA of the chemotactic cytokine IL-8 is upregulated under the influence of APN/CD13 ligation. Although the in vivo ligand as well as possible cooperating membrane molecules remains to be identified, our results suggest that the membrane ectoenzyme APN/CD13 is a novel signal transduction molecule in monocytes. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805970     DOI: 10.1006/cimm.2000.1629

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  40 in total

1.  The Drosophila slamdance gene: a mutation in an aminopeptidase can cause seizure, paralysis and neuronal failure.

Authors:  HaiGuang Zhang; Jeff Tan; Elaine Reynolds; Daniel Kuebler; Sally Faulhaber; Mark Tanouye
Journal:  Genetics       Date:  2002-11       Impact factor: 4.562

Review 2.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

3.  Tyrosine phosphorylation of CD13 regulates inflammatory cell-cell adhesion and monocyte trafficking.

Authors:  Jaganathan Subramani; Mallika Ghosh; M Mamunur Rahman; Leslie A Caromile; Claire Gerber; Karim Rezaul; David K Han; Linda H Shapiro
Journal:  J Immunol       Date:  2013-08-30       Impact factor: 5.422

Review 4.  CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders.

Authors:  Chenyang Lu; Mohammad A Amin; David A Fox
Journal:  J Immunol       Date:  2020-01-01       Impact factor: 5.422

5.  Angiogenic and Arthritogenic Properties of the Soluble Form of CD13.

Authors:  Yuxuan Du; Chenyang Lu; Rachel L Morgan; William A Stinson; Phillip L Campbell; Ellen Cealey; Wenyi Fu; Nicholas J Lepore; Jonatan L Hervoso; Huadong Cui; Andrew G Urquhart; Jeffrey N Lawton; Kevin C Chung; David A Fox; Mohammad A Amin
Journal:  J Immunol       Date:  2019-06-12       Impact factor: 5.422

Review 6.  Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review.

Authors:  Bart Stragier; Dimitri De Bundel; Sophie Sarre; Ilse Smolders; Georges Vauquelin; Alain Dupont; Yvette Michotte; Patrick Vanderheyden
Journal:  Heart Fail Rev       Date:  2007-11-08       Impact factor: 4.214

7.  Structural basis for multifunctional roles of mammalian aminopeptidase N.

Authors:  Lang Chen; Yi-Lun Lin; Guiqing Peng; Fang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-15       Impact factor: 11.205

Review 8.  The neovasculature homing motif NGR: more than meets the eye.

Authors:  Angelo Corti; Flavio Curnis; Wadih Arap; Renata Pasqualini
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113

9.  Changes in monocytic expression of aminopeptidase N/CD13 after major trauma.

Authors:  G Huschak; K Zur Nieden; R Stuttmann; D Riemann
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

10.  Human coronavirus 229E binds to CD13 in rafts and enters the cell through caveolae.

Authors:  Ryuji Nomura; Asuka Kiyota; Etsuko Suzaki; Katsuko Kataoka; Yoshihide Ohe; Kaoru Miyamoto; Takao Senda; Toyoshi Fujimoto
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.